LEA.135 Expression: Identifies low-risk patients with breast ductal carcinoma in situ

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2933-2937

  Baltayan, Armine ^a   Naritoku, Wesley Y ^a   Chaiwun, Benjapom ^a   Tsao Wei, Denice D ^a   Groshen, Susan ^a   Hern, Roger A ^b   Gusterson, Barry A ^c   Taylor, Clive R ^a   Imam, S Ashraf ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

Author keywords

Breast ductal carcinoma in situ; LEA.135; Prognosis

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LEA 135; SIALOGLYCOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARCINOMA IN SITU; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; NEOPLASM RECURRENCE, LOCAL; PARAFFIN EMBEDDING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0036765697     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lagios MD: Duct carcinoma in situ: pathology and treatment. Surg Clin N Am 70: 853-871, 1990.
2. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K and Andersen JA: Ductal carcinoma in situ of the female breast: short-term results of a prospective nationwide study. Am J Surg Pathol 16: 1183-1196, 1992.
3. Schwartz GF, Finkel GC, Carcia JC and Patchefsky AS: Subclinical ductal carcinoma in situ of the breast: treatment by local excision and surveillance alone. Cancer 70: 2468-2474, 1992.
4. Bellamy CO, McDonald C, Salter DM, Chetty U and Anderson TJ: Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum. Pathol 24: 16-23, 1993.
5. Solin LJ, Yeh IT, Kurtz J, Fourquet A., Recht A, Kuske R, McCormick B, Cross MA, Schultz DJ, Amalric R et al.: Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment. Cancer 71: 2532-2542, 1993.
6. Poller DN, Silverstein MJ, Galea M, Locker AP, Elston CW, Blarney RW and Ellis IO: Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 7: 257-262, 1994.
7. Stratton MR, Collins N, Lakhani SR and Sloane JP: Loss of heterozygosity in ductal carcinoma in situ of the breast J Pathol 175: 195-201, 1995.
8. Page DL and Rogers LW: Carcinoma In Situ (CIS). Diagnostic Histopathology of the Breast. Edited by Page DL, Anderson TJ. Edinburgh, Churchill Livingstone 1987; pp. 157-192.
9. Tavassoli FA: Intraductal Carcinoma. Pathology of the Breast. Edited by Tavassoli FA. Connecticut, Appleton and Lange 1992, pp. 229-261.
10. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ and Zafrani B: Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11: 167-180, 1994.
11. Rosai J: Borderline epithelial lesions of the breast. Am J Surg Pathol 15: 209-221, 1991.
12. Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colbum WJ and Poller DN: A prognostic index for ductal carcinoma in situ of the breast. Cancer 77: 2267-2274, 1996.
13. Bartkova J, Barnes, DM, Millis RR and Gullick WJ: Immunohisto-chemical demonstration of c-erB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 21: 1164-1167, 1990.
14. Liu E, Thor A, He M, Barcos M, Ljung BM and Benz C: The HER2-(c-erB-2) oncogene is frequently amplified in situ carcinomas of the breast. Oncogene 7: 1027-1032, 1992.
15. Poller DN, Roberts EC, Bell JA, Elston CW, Blarney RW and Ellis IO: P53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 24: 463-468, 1993.
16. O'Malley FP, Vnencak-Jones CL, Dupont WD, Parl F, Manning S and Page DL: p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast: immunohistochemical and sequencing data. Lab Invest 71: 67-72, 1994.
17. Imam SA, Esteban EF, Young LL and Taylor CR: Generation of a murine monoclonal antibody to normal mammary epithelium using mice rendered tolerant to malignant mammary epithelium. J Histochem Cytochem 42: 585-591, 1994.
18. Imam SA, Pathak S, Brown N, Yilmaz A and Taylor CR: Development of tumorigenicity and rearrangement of chromosome I correlates with down-regulation of cell-surface glycoproteins in human mammary carcinoma cell lines. Anticancer Res 14: 229-236, 1994.
19. Imam SA, Esteban EF, Chen RS, Cardiff RD and Taylor CR: Identification of a cell-surface antigen (LEA.135) associated with favorable prognosis in human breast cancer. Cancer Res 53: 3233-3236, 1993.
20. Imam SA, Chaiwun B, Wang MJ, Kim MS, Morris MM, Groshen SG, Neveille AM, Tarloni H, Cote RJ and Taylor CR: A sialoglycoprotein (LEA.135) associated with favorable prognosis of patient with lymph node-negative primary breast carcinoma. Anticancer Res 16: 3043-8, 1996.
21. Imam SA, Stathopoulos E, Holland SL, Epstein AL and Taylor CR: Characterization of a cell surface molecule expressed on B-lymphocytes and Hodgkin's cells. Cancer Res 50: 1650-1657, 1990.
22. Kaplan EL and Meier P: Nonparametric estimation form incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
23. Miller RG Jr: Survival Analysis. New York, John Wiley & Sons 1981; pp. 44-5, 94-98.
24. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Sutart SG, Udove J, Ullrich A et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
25. Bur ME, Zimarowski MJ, Schnitt SJ, Baker S and Lew R: Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 69: 1174-1181, 1992.
26. Poller DN, Snead DR, Roberts EC, Galea M, Bell JA, Gilmour A, Elston CW, Blarney RW and Ellis IO: Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 o0ncoprotein. Br J Cancer 68: 156-161, 1993.